key: cord-0935312-dmhn4dhr
authors: Robb, Calum T.; Goepp, Marie; Rossi, Adriano G.; Yao, Chengcan
title: Non‐steroidal anti‐inflammatory drugs, prostaglandins and COVID‐19
date: 2020-07-23
journal: Br J Pharmacol
DOI: 10.1111/bph.15206
sha: d47ccecfac423715198e36a149d953d24e849dc0
doc_id: 935312
cord_uid: dmhn4dhr

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the cause of the novel coronavirus disease 2019 (COVID‐19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine nor efficient treatment strategies against COVID‐19. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain and inflammation (common symptoms of COVID‐19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxygenase enzymes. PGs can exert either pro‐ or anti‐inflammatory effects depending on the inflammatory scenario. In this review, we implicate the potential roles that NSAIDs and PGs may play during SARS‐CoV‐2 infection and the development and progression of COVID‐19.

al., 2013) , NSAIDs were found to cause more prolonged illness or complications when taken during respiratory tract infections (Le Bourgeois et al., 2016; Voiriot et al., 2019) . It was reported that use of NSAIDs for fever or non-rheumatologic pain during the early stages of infection increased the risk of severe bacterial superinfection (Micallef et al., 2020) . NSAIDs may increase hypercoagulation and the incidence of thrombosis due to decreased thrombomodulin (Schmidt et al., 2011 , Rabausch et al., 2005 , a particular concern given that COVID-19 patients often have coagulation abnormalities and increased vascular clotting (Levi et al., 2020) . It is plausible that NSAIDs may possibly inhibit protective host immune reactions against coronavirus replication and enhance the pro-inflammatory cytokine storm observed in lungs of COVID-19 patients, e.g. through activation of inflammatory macrophages (Wu and Meydani, 2008) . Moreover, as SARS-CoV-2 can infect human gut enterocytes (Lamers et al., 2020) it is important to decipher if NSAIDs synergise with SARS-CoV-2 infection to potentiate severe intestinal damage.

However, do NSAIDs have any potential beneficial effects on the risk of infection with SARS-CoV-2 and/or COVID-19 severity? In a retrospective cohort study, Rentsch et al. found that exposure to NSAIDs (-365 to -14 days prior to baseline) was modestly associated with increased likelihood of COVID-19 infection [multivariable OR (odds ratio) 1.27, 95% CI (confidence interval) 1.02-1.58], was not associated with hospitalization (P=0.19) and had a negative trend of association with intensive care (P=0.08) (Rentsch et al., 2020) . In this study, information of NSAIDs only obtained from pharmacy fill was counted, but individuals assigned as non-NSAID users were still likely to get NSAIDs over the counter. In another study, Freites et al. found that use of NSAIDs was associated with reduced risk of hospital admission of COVID-19 patients who had chronic inflammatory rheumatic disease (OR 0.37, 95% CI 0.15-0.91, P=0.03) (Freites et al., 2020) . Castro et al. reported that prescription of ibuprofen and naproxen (both NSAIDs), was also associated with reduced hospitalization among 2,271 individuals who tested positive for and OR 0.388, 95% Cl 0.144-0.930, respectively) after adjustments for age, sex, race, ethnicity, site and combined comorbidity index (Castro et al., 2020) . Among hospitalized COVID-19positive individuals, 29 out of 34 patients premedicated with ibuprofen (adjusted OR 0.421, 95% CI 0.139-1.046) and 6 out of 7 patients premedicated with Naproxen (adjusted OR 0.362, 95% CI 0.019-2.269) did not require mechanical ventilation during hospitalization (Castro et al., 2020) . Huh et al. performed a large case-control study assessing the relationships of the risk of COVID-19 and the use of various drugs in 65,149 adult subjects (>18 years old, 7.9% were tested COVID-19 positive) using a national wide claims database of South Korea. They found that prior exposure to aspirin significantly associated with reduced risk of developing , 95% CI 0.14-0.58, P<0.001), whilst prior use of COX-2 inhibitors did not significantly reduce the risk (Huh et al., 2020) . Interestingly, Hong et al. have recently performed a pilot trial to treat COVID-19 patients with Celebrex (also known as celecoxib, that specifically targets COX-2) at either 0.2 g twice or once a day . The remission rates of COVID-19 disease for full/high (0.2 g twice a day) and half/medium (0.2 g once a day) doses of Celebrex and control groups were 100%, 82% and 57%, respectively . Celebrex treatment also improved pulmonary opacification and pneumonia faster than control group based on chest CT scan results. This study suggested that Celebrex may promote the recovery of ordinary and severe cases of COVID-19 and prevent the progression of severe disease to a critical stage . Low dose of celecoxib (i.e. 0.2 g once a day) used in the Hong and colleague's study was associated with a small increase in the risk (relative risk 1.35, 95% CI 1.00-1.82) of nonfatal myocardial infarction, but high dose of celecoxib (i.e. 0.2 g twice a day) was not associated with increased risk of myocardial infarction (relative risk 1.05, 95% CI 0.33-3.35) (García Rodríguez et al., 2008) . These findings may thus be indicative of the safety and efficiency for use of such doses of celecoxib in COVID-19 patients who have known cardiovascular conditions. These (pharma)epidemiological and clinical observations suggest that NSAIDs may be beneficial in controlling the development of severe COVID-19. The types and doses of NSAIDs determine their capability of inhibiting enzymatic activities of COX-1 or COX-2 or both, which affects the production profile of downstream eicosanoids, resulting in varied sideeffects in the cardiovascular, gastrointestinal, renal and other systems (García Rodríguez et al., 2008; Bhala et al., 2013; Little et al., 2013) . However, the information for exposure of NSAIDs (e.g. drug types, doses, exposure time etc) in the above epidemiological studies was unclear as they were mainly defined based on electronic health records. Lack of such information impedes further assessment of clinical benefits or harm of NSAIDs. Therefore, large scale, doubleblinded, randomized and well-controlled clinical trials are warranted to thoroughly assess the effects of specific NSAIDs at appropriate doses in prevention and treatment of COVID-19 whilst also attempting to avoid their known side effects.

Moreover, another NSAID, indomethacin, has shown potential antiviral activity against human SARS-CoV-1 and canine coronavirus (Amici et al., 2006) . Indomethacin does not affect coronavirus binding or entry into host cells, but instead acts by blocking viral RNA synthesis in vitro. Oral administration of indomethacin (1 mg/kg/d [equivalent ~40 mg/kg for a 70 kg human, less than the low-medium dose of 75 mg daily used in adult patients] for 4 days starting on day 4 post-infection) markedly reduced (by ~2-3 orders) shedding of canine CoV RNA in the faeces of dogs infected with canine CoV, but this antiviral effect was reversed upon suspension of indomethacin treatment (Xu et al., 2020b) . Indomethacin has also been suggested to pose potent anti-viral activity against SARS-CoV-2-infected Vero E6 cells in vitro and canine CoV-infected dogs in vivo (Xu et al., 2020b) . A very recent study based on a multistage model-based approach showed that treatment with the sustain-release formulation of indomethacin at the dose of 75 mg twice-a-day (high dose used clinically according to García Rodríguez et al., 2008) is expected to achieve a complete response in three days for the treatment in patients infected by SARS-CoV-2, suggesting that indomethacin could be considered as a promising candidate for the treatment of COVID-19 (Gomeni et al., 2020; Koch et al., 2020) . The anti-viral capacity of indomethacin is conferred by activation of protein kinase R independently of interferon (IFN) and dsRNA (Amici et al., 2015) but may be via interactions with aldoketo reductases, aldose reductases, peroxisome proliferator activated receptor gamma and cannabinoid receptor 2 (Xu et al., 2020b) . Conversely, it is important to report that indomethacin and other NSAIDs (comprising coxibs) are associated with nephrotoxicity (McCarthy et al., 1982; Delaney and Segel, 1985; Whelton, 1999) . As a result, such NSAIDs are not recommended for use in patients with clinically complicated SARS-CoV-2 infections with deficiencies in renal function, where renal blood flow is maintained by the contributory effects of vasodilator PGs (Grosser et al., 2006) or with gastrointestinal risk factors (Capuano et al., 2020) . Therefore, such clinically complex SARS-CoV-2 infections constitute a contraindication to the use of NSAIDs since their use may predispose to these wellknown side-effects of NSAIDs (Patrignani and Patrono, 2015) . Importantly, indomethacin is also known to have coronary vasoconstrictor effects via blockade of vasodilatory PG synthesis or to a direct drug effect, suggesting that in patients with severe coronary-artery disease indomethacin should be used with caution (Friedman et al., 1981) . Using an original virtual screening protocol, celecoxib at 50 µM (much higher than its maximum serum concentration of 1.8 µM when 200 mg/d is used) was predicted to suppresses the activity of the main chymotrypsin-like protease (a key target for antiviral drugs) of SARS-CoV-2 by ~12% (Gimeno et al., 2020) . In addition, naproxen has also been shown to possess antiviral activity against influenza A and B viruses by interfering with the RNA replication process (Zheng et al., 2019) . Moreover, ibuprofen was reported to enhance ACE2 expression from diabetic rat cardiac tissues (Qiao et al., 2015) , while celecoxib was shown to repress expression of TMPRSS2 in human prostate cancer cells (Kashiwagi et al., 2014) . Given the protective action of ACE2 in ALI Kuba et al., 2005; Kuba et al., 2006; Imai et al., 2008) and the negative correlation between ACE2 expression and SARS-CoV-2 severe outcomes , NSAIDs may help reduce COVID-19 disease severity due to SARS-CoV-2 infection if they can upregulate and down-regulate ACE2 and TMPRSS2 in the lung, respectively.

NSAIDs serve to reduce inflammation by targeting cyclooxygenases (i.e., COXs including COX-1 and COX-2) and inhibiting biosynthesis of prostaglandins (PGs), a group of important lipid mediators. PGs are formed when arachidonic acid (AA) is released from cell membrane phospholipids by the actions of cytosolic phospholipase A (cPLA) and converted to PGH2 by COXs. COX-1 is constitutively expressed in most cells, whereas COX-2 is induced upon the initiation of inflammation (Dubois et al., 1998) . PGH2 is unstable and converted into each PG by their specific synthases. PGDSs (including LPGDS and HPGDS), PGESs (including mPGES-1, mPGES-2 and cPGES), PGFSs (including AKR1C3 and AKR1B1), PGIS and TXAS lead to production of PGD2, PGE2, PGF2α, PGI2 and TXA2, respectively (Figure 1 ).

Single-cell RNA sequencing analysis (Du et al., 2017) reveals that cPLAs, COXs and PG synthases are expressed in normal human lung cells from a healthy young individual ( Figure   2 ). For example, COX-1 is expressed in immune cells such as dendritic cells (DCs) and mast cells while COX-2 is broadly but moderately expressed by epithelial (e.g. AT1), stromal (e.g. matrix fibroblasts) and immune (e.g. monocytes/macrophages, DC and mast cells) cells.

Endothelial, stromal, mast, DC and natural killer (NK) cells highly express PGDSs, but only matrix fibroblasts and lymphatic endothelial cells moderately express mPGES-1, the inducible enzyme that mediates PGE2 biosynthesis in vivo, in the normal lung.

PGs exert their autocrine and paracrine effects via activation of nine types and subtypes of rhodopsin-like transmembrane spanning G protein-coupled receptors. These are the PGE2 receptors (EP1, EP2, EP3 and EP4), PGD2 receptors (DP1 and DP2), PGF2 receptor (FP), PGI2 receptor (IP) and TXA2 receptor (TP). These PG receptors initiate multiple and distinct Fdownstream signalling pathways (Figure 1 ) and thus function as double-edged swords during diverse physiological and pathological processes where they can play conflicting roles (Narumiya and FitzGerald, 2001; Yao and Narumiya, 2019) . In the healthy lung, NK and T cells express DP1 while mast cells mildly express DP2. Among four PGE2 receptors, EP4 and EP2 are expressed on stromal cells and nearly all immune cell types, but at very low levels on alveolar epithelial (AT1 or AT2) cells. IP is highly expressed on stromal cells while TP is expressed on vascular endothelial cells (Figure 2 ).

PGs are found in most mammalian cells and tissues and can promote both the initiation and resolution of inflammation, depending on local concentrations, disease setting and timing of action . Fluctuations in expression of these synthases within cells recruited to sites of inflammation governs the production profiles of PGs. Although PGE2 is detectable in bronchoalveolar lavage (BAL) fluids (rather than bronchial wash fluids) taken from healthy individuals, its level (1.6 pM) is 3-8 folds lower than levels of PGD2, PGF2 and TXB2 (a stable TXA2 metabolite) (Gouveia-Figueira et al., 2017) . PG levels are usually elevated in response to inflammatory or noxious stimuli. For example, PGE2 compared to other PGs was found to be significantly upregulated in BAL fluids of individuals after exposure to biodiesel exhaust (Gouveia-Figueira et al., 2017) . Plasma levels of PGE2 were increased in patients from early stage (within the first week, 1,966 pg/ml ≈ 5.6 nM) of SARS-CoV-1 infection and lasted to the late stage (2-3 weeks, 2,170 pg/ml ≈ 6.2 nM) of infection compared to that in plasma from control individuals (1,300 pg/ml≈ 3.7 nM) (Lee et al., 2004) . This is associated with induction of COX-2 expression as the SARS-CoV-1 N protein binds directly to two regulatory elements (i.e. NF-κB and C/EBP binding sites) of the COX-2 promoter (Yan et al., 2006) . By performing proteomic and metabolomic profiling of sera from COVID-19 patients and healthy individuals, Shen et al. found a remarkable elevation of serum amyloid A 1 (SAA1), SAA2, SAA4 and other inflammation markers (e.g. C-reactive protein, SAP and SERPINA3) in severe COVID-19 patients compared to non-severe COVID-19 patients and healthy individuals (Shen et al., 2020) . SAAs can enhance COX-dependent AA metabolism and PG production including PGE2, PGF2 and TXA2 in many types of human cells, such as monocytes, macrophages and fibroblasts, through NF-κB activation (Malle et al., 1997; Li et al., 2017) . Similarly, Yan et al. found upregulation of genes associated with the PGE2 synthesis pathway including PLAs, COX-1, COX-2 and PTGES3 during the disease progression of COVID-19 patients compared to that of healthy individuals in a longitudinal transcriptome This article is protected by copyright. All rights reserved. analysis of peripheral blood mononuclear cells (Yan et al., 2020) . In agreement with these findings, Hong et al. observed significantly higher (~10 folds) levels of PGE2 in urine samples of COVID-19 patients compared to healthy individuals. PGE2 in COVID-19 patient's urine remained at high-levels for 5-12 days post hospital admission with routine treatment, but its level was reduced after taking oral Celebrex, a selective COX-2 inhibitor .

However, urinary PGE2 is formed in the kidney does not represent systemic PG levels. To assess systemic production of PGs, detection of circulation levels of their metabolites, e.g.

PGE-M, PGD-M and PGI-M, in both blood and urine is needed. Moreover, PGs and their metabolites present in the lung, e.g. BAL fluid, will also be highly informative.

Traditionally, PGs have been viewed as inflammatory mediators connecting innate immunity to phases of acute inflammation with pro-inflammatory cytokines (TNF-α, IL-1β) and LPS known to induce expression of inducible COX-2 and mPGES-1 (Díaz-Muñoz et al., 2010) .

However, COX-2 and mPGES-1 expression is also observed in chronically inflamed tissues including joints of rheumatoid arthritis patients, colons of inflammatory bowel disease patients and cancerous tumours and their microenvironment (Ricciotti and FitzGerlad, 2011; Wang and DuBois, 2018) . Therefore, PGs appear to play integral roles during both acute inflammation and chronic inflammatory diseases. Gordon et al. systemically mapped the interaction landscape between SARS-CoV2 proteins, including 4 structural (S, E, M, N) proteins and nonstructural proteins (Nsp), and human host cell proteins, and predicted numerous host proteins as potential drug targets. Remarkably, they found that non-structural proteins Nsp7 and Nsp14 interacted with PTGES2 (encoding mPGES-2) and PRKACA (encoding the catalytic subunit α of protein kinase A, PKA), respectively (Gordon et al., 2020) . mPGES-2 mediates biosynthesis of PGE2, which mainly activates the cAMP-PKA pathway and its receptors EP4 and EP2 are highly expressed in lung cells. Thus, targeting mPGES-2 by NSAIDs (such as indomethacin, Yamada et al., 2005) can not only inhibit PGE2 production but also interrupt virus-host cell interaction. In addition, mPGES-1 inhibition may be of clinical benefit during PGE2-induced inflammatory episodes, including COVID-19 associated ARDS (Smeitink et al., 2020) . Thus, targeting respective PG synthase might represent alternative and effective strategies in attempt to alleviate adverse side-effects of NSAIDs that result from non-specific inhibition of all prostaglandins downstream of PGH2.

What may be the underlying scientific rationale and biological mechanisms for either beneficial or harmful effects of NSAIDs on the risk of development of COVID-19 or disease severity?

What are the fundamental mechanisms underlying the risk factors (e.g. age, male sex and underlying healthy conditions) for developing severe to critical disease and death in COVID-19 patients? (Docherty et al., 2020; Williamson et al., 2020) . Are PGs involved in the risks of and MERS-CoV in Huh-7 cells (Yan et al., 2019) . Accordingly, Shen et al. used metabolomic assays to decipher that serum levels of arachidonate (20:4n6) were significantly reduced in COVID-19 patients which was negatively associated with disease severity (Shen et al., 2020) , suggesting that decreased levels of AA may lead to lack of inhibition of SARS-CoV-2 replication in COVID-19 patients. In light of this, it is suggested that oral or intravenous administration of AA and other unsaturated fatty acids may enhance recovery in COVID-19 patients (Das, 2020) . On the other hand, decrease of AA levels could also be explained as a result of facilitation of AA metabolism, i.e. converting into downstream PGs. Indeed, upregulated gene expression of COX-1, COX-2 and PTGES3 and increased PGE2 levels are found in COVID-19 patients (Yan et al., 2020; Hong et al., 2020) . Furthermore, cPLA2α serves to function in the release of AA from cell membrane lipids and subsequent production of PGs.

In the human lung, cPLA2 genes are highly expressed in endothelial and epithelial cells ( Figure 2) where CoVs (SARS-CoV-1 and SARS-CoV-2) first attach. Expression of several PLA2 genes (e.g. PLA2G4A, PLA2G4C, PLA2G7, PLA2G15) are upregulated in COVID-19 patients compared to healthy controls, and their expression reduces to normal levels when patients recover from COVID-19 (Yan et al., 2020) . Inhibition of cPLA2α activity using pyrrolidine-2 significantly reduced viral replication and formation of double membrane vesicles in HCoV-229E infected Huh-7 cells and MERS-CoV infected Huh-7/Vero cells (Müller et al., 2018) , implying that anti-CoV treatments harnessing cPLA2α inhibition may be of potential therapeutic benefit. It remains unknow whether cPLA2α and its products (i.e. fatty acids) regulate CoV replication directly or indirectly through their further downstream metabolites of fatty acids, e.g. PGs. Below we will focus on discussion of possible functions of PGD2 and PGE2 even though other PGs may also influence SARS-CoV-2 infection and COVID-19. For example, PGI2 and TXA2 respectively can reduce and promote thrombosis, a hallmark complication that occurs in nearly half of critically ill COVID-19 patients and which contributes to mortality (Klok et al., 2020; Wise, 2020) . Moreover, the vasodilatory and endothelial cell effects of PGs are well described, however, here we focus on discussing PG's roles in COVID-19 immunopathology.

The exact mechanisms behind the development of systemic coagulopathy and acquired thrombophilia defined in the majority of COVID-19 cases which can lead to venous, arterial and microvascular thrombosis remain unclear (Becker, 2020) . Indeed, clinical characteristics of COVID-19 include elevated D-dimer levels, prolonged thrombin time and thrombocytopenia (platelet count <150,000/µL), therefore suggesting an increased possibility of disseminated intravascular coagulation or pre-disseminated intravascular coagulation (Guan et al., 2020) . Moreover, pooled analysis suggests that significant increases in D-dimer levels as a predictor of adverse outcomes was regularly observed in COVID-19 patient blood, implying the presence of underlying coagulopathy (Lippi and Favaloro, 2020) . Although Ddimer levels can be altered by numerous inflammatory processes, in cases of COVID-19 it is almost certainly due to intra-vascular thrombosis (Leonard-Lorant et al., 2020; Cui et al., 2020) . A retrospective cohort study found that on admission, increased D-dimer levels (>1000 ng/mL) was associated with increased risk of death in hospitalised COVID-19 patients (Zhou et al., 2020a) . In COVID-19 patients, increased D-dimer levels continues to be a persistent marker of poor outcome (Bikdeli et al., 2020) . Klok et al. reported a high incidence of 31% thrombotic complications in ICU patients with COVID-19, of which venous thromboembolic events were most common (27%) (Klok et al., 2020) . Furthermore, in 183 consecutive patients with COVID-19 pneumonia, abnormal coagulation parameters and poor prognosis were recorded, and patients who died (compared to survivors) exhibited increased D-dimer levels, fibrinogen degradation products and longer PT and APTT values .

Pathological characteristics of COVID-19 infection include platelet-fibrin thrombosis and intravascular megakaryocytes in all major organs, including the heart and lungs (Fox et al., 2020) . Megakaryocytes are responsible for the production of platelets therefore the employment of anti-platelet agents may be of clinical benefit during COVID-19 pathogenesis.

Aspirin is a broadly studied anti-platelet drug which exerts its cardioprotective effects via irreversible inhibition of platelet COX-1 thus blocking TXA2 production from activated platelets, and so decreases pro-thrombotic events. However, aspirin does not confer plateletspecific effects and in other cell types (via inhibition of COX-1 and in some cases COX-2) it can decrease prostanoid production, e.g. PGI2, which serves to inhibit platelet aggregation (conversely to TXA2). Interestingly, as determined by a pharmacodynamic interaction study in healthy volunteers, other NSAIDs including ibuprofen, naproxen, indomethacin and tiaprofenic acid all block the anti-platelet effect of aspirin, whereas celecoxib and sulindac did not exhibit any significant anti-platelet effects (Gladding et al., 2008) . Although aspirin can inhibit viral replication, confer anti-inflammatory and anti-coagulant effects, as present it has not been thoroughly investigated in the treatment of thrombosis during COVID-19. However, COVID-19 clinical trials involving aspirin administration are on-going. That said, PGs (whose production is blocked by NSAIDs) can also confer anti-platelet effects and therefore also merit COVID-19 clinical attention. For example, it has been long understood that within the PG family, PGE1 is the most potent inhibitor of ADP-induced platelet aggregation whereas PGE2 possesses roughly a fifth of its activity (Irion and Blombäck, 1969). PGE2-EP4 signalling does effectively inhibit platelet aggregation at high concentrations (>1x10 -6 M) (Macintyre and Gordon, 1975) and akin to PGI2, PGD2 can also inhibit platelet aggregation (Smith et al., 1974) , but PGE2-EP3 signalling augments platelet aggregation (Friedman et al., 2015) .

Ageing is associated with upregulated gene expression of PG synthases (e.g. COX-2 and mPGES-1) and elevated levels of prostaglandins (e.g. PGE2, PGD2, PGF2 and TXB2) in humans (Li et al., 2015) . Similarly, Vijay et al. found that expression of PLA2 group IID (PLA2G2D) was increased in aged mouse lungs compared to younger mice, leading to augmented production of PGD2, PGE2, PGF2 and TXB2 in lungs in response to SARS-CoV-1 infection (Vijay et al., 2015) . Differential gene expression deciphered that the major source of PLA2G2D was lung resident CD11c + cells, e.g. alveolar macrophages and DCs (Vijay et al., 2015) . Strikingly, aged mice with deficiency in PLA2G2D were protected from SARS-CoV-1 infection, exhibited enhanced virus-specific cytotoxic CD8 T cell responses, and increased migration of respiratory DCs to draining lymph nodes (Vijay et al., 2015) . PGD2 may contribute to SARA-CoV-1 infection as treatment with exogenous PGD2 in young mice decreased respiratory DC migration, while treatment with a DP1 antagonist enhanced respiratory DC migration, CD8 T cell responses and the kinetics of virus clearance in lungs of aged, SARS-CoV-1 infected mice (Zhao et al., 2011) . Enhanced T cell responses are of integral importance because reduced T cell responses are associated with higher mortality rates in SARS-CoV-1-infected mice (Zhao et al., 2009; Channappanavar et al., 2014) and lymphopenia is also associated with disease progression of COVID-19 . Vijay and colleagues further showed that PGD2-DP1 signalling works together with type I IFN signalling to induce expression of pyrin domain only-containing protein 3 (PYDC3) that diminishes neurotropic CoV-induced inflammasome activation and pro-inflammatory cytokine (like IL-1β) expression in mouse brain, thus preventing chronic inflammation and tissue damage (Vijay et al., 2017) . Interestingly, DP1 signalling in human macrophages also up-regulates POP3, a putative functional analogue of mouse PYDC3, suggesting that PGD2 similarly modulates inflammasomes in human cells (Vijay et al., 2017) . These studies thus suggest that targeting the PGD2-DP1 pathway may be helpful to control SARS-CoV infection in older humans.

Furthermore, SARS-CoV-2 may cause mast cell activation via toll-like receptors (TLR) or inducing crosslink of IgE-FcεRI and subsequent production of PGD2, where use of mast cell stabilisers, including beta receptor agonists are highlighted as potential therapeutic targets during SARS-CoV-2 infection due to their efficient inhibition of PGD2 (Kilinç and Kilinç, 2020) . Infection with respiratory syncytial virus (RSV) upregulates HPGDS expression and increases PGD2 secretion by cultured human primary airway epithelial cells (Werder et al., 2018) . Blocking the DP2 receptor decreased viral load, immunopathology, and morbidity in a neonatal mouse model of severe viral bronchiolitis (Werder et al., 2018) . Interestingly, the beneficial effects of DP2 antagonism is abrogated by concurrent blocking of the DP1 receptor and DP1 agonism upregulates type III IFN (i.e. IFN-) production and IFN-stimulated gene expression, accelerating viral clearance (Werder et al., 2018) . This finding suggests reciprocal effects of DP1 and DP2 in RVS infection, although it is contrary to the findings of the pathogenic role of DP1 during SARS-CoV-1 infection (Zhao et al., 2011) . Therefore, investigations should attempt to decipher the actions of PGD2, DP1 and DP2 on SARS-CoV-2 infection and during development of COVID-19.

PGE2 is considered an anti-inflammatory agent in various lung conditions including acute lung injury, asthma, fibrosis and bacterial infections (Vancheri et al., 2004; Birrell et al., 2015; Lundequist et al., 2010; Felton et al., 2018) . But it can also exert inflammatory effects in certain condition such as COPD, lung cancer and certain viral infections (Bonanno et al., 2016; Dehle et al., 2013; Nakanishi and Rosenberg, 2013) . Infection with various viruses, e.g. herpes simplex virus, rotavirus, influenza A virus (IAV), induces expression of COX-2 and mPGES-1, resulting in overproduction of PGE2, which in turn plays a role in viral infection directly by modulating viral binding, replication and gene expression and/or indirectly by regulating the host immune responses (reviewed by Sander et al., 2017) . Indeed, elevated levels of PGE2 were observed in patients infected with SARS-CoV-1 or SARS-CoV-2 (Lee et al., 2004; . Furthermore, Smeitink and colleagues speculate that in males, increased PGE2 may correlate with enhanced COVID-19 severity by augmenting thrombotic responses (Smeitink et al., 2020) . This may be in part due to effects of PGE2 in promoting intravascular thrombosis via its platelet receptor, EP3 (Gross et al., 2007) . Elevated levels of PGE2 may further enhance SARS-CoV-2 cell entry. Indeed, elevated PGE2 does enhance clathrin-mediated endocytosis of bovine ephemeral fever virus (Cheng et al., 2015) . Here we will discuss potential actions of PGE2 in COVID-19 based on the current state of the knowledge of this lipid in modulation of immune responses during infections or under inflammatory conditions (Figure 3 ).

Infection with SARS-CoV-2 ligates various pathogen recognition receptors, e.g. TLRs and/or RIG-I-like receptors, and activates transcription factors such as IFN regulatory factor 3 (IRF3) and nuclear factor κB (NF-κB) that are responsible for expression of type I and III IFNs and pro-inflammatory mediators (e.g. TNF-α, IL-6 and PGE2) respectively. Secreted IFNs then activate the JAK-STAT1/2 pathway to trigger production of IFN-stimulated genes (ISGs) that directly recognise and execute antiviral functions (Park and Iwasaki, 2020) . PGE2 has been reported to inhibit production of type I IFNs. For example, after infection with IAV, mPGES-1 deficient macrophages exhibit an early increase in phosphor-IRF3 compared to WT macrophages, augmented type I IFN and decreased viral load, which was drastically inhibited by addition of exogenous PGE2 (Coulombe et al., 2014) . Fabricius and colleagues reported that PGE2 inhibited secretion of IFN-α by TLR-activated human plasmacytoid DCs through its EP2 and EP4 receptor-mediated suppression of IRF7 (Fabricius et al., 2010) . Patients with mild to moderate COVID-19 had high type I IFN responses, while severe COVID-19 patients had impaired type I IFN activity and down-regulated ISGs (Hadjadj et al., 2020) . It remains to be clarified whether severe COVID-19 patients have higher levels of PGE2, and if so, whether this represents a mechanism evolved by SARS-CoV-2 for suppression of type I IFN production and function. Moreover, as DP1 promotes type III IFN production and signalling, contributes to RSV viral clearance (Werder et al., 2018) and PGE2 receptors EP2 and EP4 both activate the cAMP-PKA pathway (akin to DP1), it would be of interest to investigate whether PGE2 has different effects on production and functions of type I and III IFNs during SARS-CoV-2 infection.

syndrome, a leading cause of mortality in severe COVID-19 patients (Mehta et al., 2020) . Proinflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α and chemokines including CCL2/MCP1, CCL3/MIP1a and CXCL10/IP10 are produced from epithelial cells, monocytes and macrophages shortly after clinical symptoms appear (Mehta et al., 2020) . Many clinical trials have been set up to treat COVID-19 by targeting pathways relating to pro-inflammatory cytokine production, e.g. IL-1 and IL-6 (Merad and Martin, 2020; Bonam et al., 2020) . NF-κB is the key transcription factor responsible for induction of pro-inflammatory cytokines.

Activation of NF-κB can stimulate gene expression of inducible COX-2 and mPGES-1 in many cell types, leading to production of PGE2. COX-2-dependent production PGE2 acts autocrinally and/or paracrinally on NF-B stimulation for expanding of pro-inflammatory cytokines and chemokines through the EP2 (maybe also EP4) receptor (Aoki et al., 2017; Yao and Narumiya, 2019) . For example, PGE2 mediates NF-B-dependent IL-8 gene transcription and protein secretion in human cells such as pulmonary microvascular endothelial cells, nasal polypderived fibroblasts and HEK293 cells, most likely through the EP4 receptor (Neuschäfer-Rube et al., Aso et al., 2012; Cho et al., 2014) . Thus, amplification of the PGE2-NK-B circus likely contributes to the cytokine storm and hyperinflammation observed in COVID-19.

PGE2 on IL-6 production. Elevated IL-6 and IL-6-activated genes have been found in peripheral blood of COVID-19 patients Hadjadj et al., 2020) . PGE2 has been reported to have contradictory effects on IL-6 production which likely depends on the stimuli. For example, PGE2 and EP4 agonism inhibit LPS-induced pro-inflammatory cytokines (e.g. IL-6 and TNF-α) and promote systemic inflammation in multiple organs of mice (Duffin et al., 2016) . Furthermore, PGE2-EP4 signalling was also shown to suppress LPS-induced ALI partially through IL-6 and TNF-α production (Birrell et al., 2015 , Felton et al., 2018 . PGE2 also inhibited LPS-and Streptococcus pneumoniae-induced IL-6 and TNF-α production from human lung macrophages (Gill et al., 2016) . Conversely, however, injection of mineral oils induced peritoneal macrophages to release IL-6 and PGE2, which was reversed by inhibition of endogenous PGE2 signalling (Hinson et al., 1996) . In humans, PGE2 promotes IL-1βdependent production of IL-6, M-CSF and VEGF from human fibroblasts via the EP4 receptor (Inoue et al., 2002) . PGE2 also enhances induction of IL-6 and other pro-inflammatory cytokines (e.g. IL-8) upon various stimuli in monocytes, macrophages, fibroblasts and airway epithelial cells through both EP2 and/or EP4 receptors (Raychaudhuri et al., 2010; Cho et al., 2014; Chen et al., 2006; Li et al., 2011) . In return, IL-6 further up-regulates COX-2 gene expression and increases PGE2 production, working together for optimised production of other inflammatory mediators for example MMP9 (Kothari et al., 2014) . Moreover, PGE2 can promote IL-6 production in a paracrine way. For example, PGE2 promotes Th17 cells to secrete IL-17A which then stimulates fibroblast to produce proinflammatory cytokines e.g. IL-6, IL-8 and IL-1β (Paulissen et al., 2013) . 

and IL-1β secretion in macrophages derived from COVID-19 patients but not in macrophages from healthy SARS-CoV-2 naïve controls, and that chemical inhibition of NLRP3 blocks spike protein-induced IL-1β secretion ex vivo (Theobald et al., 2020) . PGE2 promotes pro-IL-1β gene expression and IL-1β secretion via a positive feedback loop (Zasłona et al., 2017) . In a mouse model of Pseudomonas aeruginosa bacterial infection, PGE2 mediates IL-1β induction, limits autophagy-mediated killing of P. aeruginosa in alveolar macrophages, and augments IL-1βmediated ALI (Martínez-Colón et al., 2018) . But there are contradictory findings on how PGE2 modulates NLRP3 inflammasome activation. PGE2 was reported to inhibit NLRP3 inflammasome activation in macrophages through its EP4 receptor and blockade of COX-2 or EP4 resulted in increased NLRP3 inflammasome activation (Mortimer et al., 2016; Sokolowska et al., 2015) . However, other authors report positive effects of PGE2 upon NLRP3 inflammasome activation and IL-1β production in macrophages and monocytes under various stimuli (Nakata et al., 2020; Zasłona et al., 2017 , Sheppe et al., 2018 . Taken together, these findings indicate context-dependent modulation of NLRP3 inflammasome activation by PGE2.

Careful examinations are thus required to clarify the impacts of PGE2 upon NLRP3 inflammasome activation, e.g. primed by different SARS-CoV-2 proteins in differential cell types.

pro-inflammatory and anti-inflammatory cytokines and generally function to eliminate pathogens. Expansion of IL-6-producing CD14 + CD16 + monocytes was observed in peripheral blood from severe COVID-19 patients (Zhou et al., 2020d; Zhang et al., 2020b) , but reduction of HLA-DR on CD14 + monocytes was found in COVID-19 patients with severe respiratory failure, which was associated with increase in IL-6 (Giamarellos-Bourboulis et al., 2020), indicative of immunosuppression. This scenario likely involves the immuno-suppressant PGE2 that can be secreted by both human monocytes and macrophages. While human macrophages use an IL-1β-independent pathway exclusively, monocytes produce PGE2 by both IL-1βindependent and IL-1β-dependent pathways, the latter involves TLR4/TRIF/IRF3 signalling (Endo et al., 2014) . Qiu et al. found an increase of CD14 + CD16 + monocytes in patients with severe sepsis or septic shock, which was positively associated with disease severity (Qiu et al., 2017) . After in vitro culture of monocytes from sepsis patients, PGE2 diminished CD14 + CD16 + monocytes after 24 hours, reduced TNF-α production but enhanced anti-inflammatory IL-10 production (Qiu et al., 2017) . High amounts of IL-1β and PGE2 are mainly produced from the classic inflammatory CD14 + CD16human monocytes after C. albicans infection (Smeekens et al., 2011) . Increase in inflammatory monocytes was indicated to be associated with increased survival rate at least in Gram-negative sepsis patients (Gainaru et al., 2018) . Hence reduction of inflammatory CD14 + monocytes by PGE2 may sustain immunosuppression and could be Single cell RNA sequencing analysis of cells in BAL fluid from COVID-19 patients suggested that monocyte-derived macrophages, but not alveolar macrophages, contribute to lung inflammation and damage in severe COVID-19 patients . Bulk RNA sequencing analysis of BAL cells also suggested increased production of chemokines like CCL2 and CXCL1 , Zhou et al., 2020e, Xiong et al., 2020 , which recruit CCR2-expressing classical monocytes and neutrophils, respectively, to the lung from peripheral blood. Interestingly, PGE2-EP2 signalling increases CCL2 and CXCL1 production from macrophages and other cells (Aoki et al., 2017, Yao and . During human monocyte/macrophage differentiation, cAMP elevating reagents like PGE2 can cause a large increase in the mRNA and protein levels of several pro-inflammatory CCL and CXCL chemokines, contributing to the pathogenesis of lung disease (Hertz et al., 2009) . Furthermore, alternatively activated M2 macrophages differentiated from monocytes promotes tissue repair by secreting reparative cytokines such as TGF-β, AREG and VEGF etc (Wynn and Vannella, 2016) . As PGE2 facilitates generation of M2 macrophages it may thus also contribute to lung fibrosis in severe COVID-19 patients.

PGE2 on NET release. The formation of neutrophil extracellular traps (NETs) is an evolutionary ancient process which involves the release of decondensed nuclear chromatin studded with various antimicrobial proteins (e.g. core histones, NE, MPO) to the extracellular space where they serve to trap and kill invading microorganisms (Brinkmann et al., 2004; Fuchs et al., 2007; Robb et al., 2014) . However, aberrant NET formation is implicated in a wide range of NET-associated diseases. Hence, NETs are regarded as double-edged swords in innate immunity (Kaplan and Radic, 2012) . Given the important role NETs play in the pathogenesis of various respiratory diseases and thrombosis, many researchers also implicate NETs as key players in the pathogenesis of COVID-19, most probably via NET-mediated release of excess IL-6 and IL-1β during cytokine storms in the COVID-19 milieu (Barnes et al., 2020; Thierry, 2020; Thierry and Roch, 2020; Mozzini and Girelli, 2020; Tomar et al., 2020) . Indeed, there is a high degree of NET-IL-1β interplay during both venous and arterial thrombosis and severe asthma (Yadav et al., 2019; Liberale et al., 2019; Lachowicz-Scroggins et al., 2019) and it's hypothesised that there may be therapeutic potential in targeting the IL-1β/NET feedback loop (Yaqinuddin and Kashir, 2020) . It is proposed that upon SARS-CoV-2 infection, activated endothelial cells recruit neutrophils where they release NETs, which in turn activates the contact pathway of coagulation, subsequently trapping and activating platelets to potentiate blood clotting (Merad and Martin, 2020) . It has been demonstrated that NETs contribute to immunothrombosis in COVID-19 ARDS where pulmonary autopsies confirmed NET-associated microthrombi with neutrophil-platelet infiltration (Middleton et al., 2020) .

Such NET-induced immunothrombosis may help explain the prothrombotic clinical presentations observed in COVID-19 patients (Middleton et al., 2020) . Indeed, NETs have been identified as potential markers of disease severity in COVID-19 and elevated NET formation in hospitalised COVID-19 patients is associated with higher risk of thrombotic episodes . Serum samples of hospitalised COVID-19 patients contained greater cell free DNA and hallmark NET associated products, including MPO-DNA complexes and citrullinated histone H3, compared to healthy control serum samples . Furthermore, serum of COVID-19 patients requiring mechanical ventilation exhibited augmented cell free DNA and MPO-DNA complexes, compared to patients breathing room air . An additional NET marker, calprotectin, was found to be present at prominently elevated levels in the blood of 172 COVID-19 patients (Shi et al., 2020a) . PGs are reported to have inhibitory effect upon NET formation. PGE2 has been demonstrated to inhibit NET formation after stem cell transplant (Domingo-Gonzalez et al., 2016) and via EP2 and EP4 mediated activation of cAMP (Shishikura et al., 2016) . After co-culture of neutrophils with cAMP-elevating reagents, PMA-induced NET formation was significantly reduced (Shishikura et al., 2016) . The adenylate cyclase toxin which vastly increases intracellular cAMP is also known to reduce NETs (Eby et al., 2014) . Interestingly, induction of intracellular cAMP production by PGE1 markedly constrains NETs induced by the pancreatic cancer cell line (AsPC-1) (Jung et al., 2019) . Importantly, CGS21680, a selective agonist of the adenosine A2A receptor (which increases intracellular cAMP) successfully diminished NET formation mediated by antiphospholipid antibodies, which increased the incidence of thrombotic events (Ali et al., 2019) . Furthermore, in mice administered antiphospholipid antibodies, CGS21680 impaired thrombosis within the inferior vena cava (Ali et al., 2019) . Here the authors also demonstrate similar inhibition of NETs via dipyridamole, an antithrombotic medication which increases extracellular adenosine and impedes cAMP breakdown (Ali et al., 2019) . Together with the known inhibitory effects of PGE2 on platelet function (Gross et al., 2007) , such evidence suggests there may be the potential for therapeutic gain in harnessing existing drugs that augment production of PGs and cAMP, and thus reduce excess NET formation and the incidence of thrombotic events during SARS-CoV-2 infection.

innate immune responses. Thirdly, hyperactivated and differentiated type 1 and 17 helper T cells (i.e. Th1 and Th17 cells, respectively) produce large amounts of pro-inflammatory cytokines (e.g. IL-2, TNF-α, IFN-, IL-6, IL-17 etc) that contribute to the cytokine storm and immunopathology, but viral infection may also activate regulatory T (Treg) cells which limit immunopathology through mechanisms like production of anti-inflammatory cytokines (e.g. IL-10). After infection with SARS-CoV-2, a significant reduction of peripheral blood CD4 + and CD8 + T cells (a phenomenon known as lymphopenia) results in moderate to severe COVID-19 patients, which is correlated with disease severity and mortality (Chen et al., 2020a; Diao et al., 2020; Tan et al., 2020) . In contrast to peripheral blood, mass lymphocyte infiltrations were observed in the lung as confirmed by post-mortem examination of a COVID-19 patient who suffered from ARDS (Tian et al., 2020) . PGE2 has multifaceted effects on modulation of T cell responses . PGE2 suppresses T cell receptor-dependent T cell activation and proliferation via EP2/EP4-mediated cAMP-PKA pathway, but this suppressive effect is weakened by enhancing CD28 co-stimulation through augmentation of PI3K signalling (Yao et al., 2013) . Following SARS-CoV-2 infection, the pathway related to CD28 signalling in T helper cells was significantly down-regulated, while the PKA pathway and PGE2 biosynthesis pathway were significantly upregulated (Zhou et al., 2020e; Yan et al., 2020) . Thus, PGE2-cAMP-PKA signalling is likely to inhibit antigendependent activation of anti-viral T cell responses in COVID-19 patients. In this view, use of NSAIDs by inhibiting endogenous PGE2 production may enhance anti-viral T cell responses in COVID-19 patients. Indeed, enhanced viral antigen-specific CD8 + and CD4 + T cell responses in lungs were found in PTGES-deficient mice where PGE2 production was largely reduced compared to WT mice post IAV infection, and this was associated with reduced viral load in PTGES-deficient animals (Coulombe et al., 2014) . Moreover, increased expression of PD-1 and TIM-3 on CD8 + T cells was detected in severe and critical COVID-19 patients (Diao et al., 2020; Zhou et al., 2020d) , suggesting T cell exhaustion may occur. Interestingly, PGE2 through EP2 and EP4 receptors synergies with PD-1 signalling to suppress mice and human cytotoxic T cell survival and function during chronic viral infection or in the tumour microenvironment. Combined blockade of COX-PGE2 signalling and PD-1/PD-L1 augments T cell responses and improves control of viral infection and tumour growth Miao et al., 2017; Sajiki et al., 2019) .

As for inflammatory T cells, PGE2 regulates Th1 cell differentiation dependently on the strengths of T cell receptor and CD28 co-stimulation and timing of PGE2 encounter (Yao et al., 2013) . Given the down-regulation of CD28 signalling, immediate upregulation of genes related PGE2 synthases (i.e., PTGS1, PTGS2, PTGES3) at the early stages post SARS-CoV-2 infection, and the kinetics of PGE2 secretion in COVID-19 patients (Zhou et al., 2020e; Yan et al., 2020; Hong et al., 2020) , it is proposed that PGE2 may inhibit the development of inflammatory IFN--producing Th1 cells, although further investigations are required. This assumption is further supported by the findings that PGE2 inhibits monocyte-derived DCs and macrophages to produce IL-12 (van der Pouw Kraan et al., 1995; Kaliński et al., 1997) , the key cytokine for generating IFN--producing Th1 cells. Of note, IFN- production from CD8 + T cells and NK cells was not significantly different in blood of non-severe and severe COVID-19 patients, but IFN- + CD4 + T cells was likely reduced in severe compared to non-severe COVID-19 patients (Qin et al., 2020; Chen et al., 2020a) . Th17 cells highly express IL-17A, IL-17F, IL-22 and GM-CSF that contribute to COVID-19 immunopathology. PGE2 stimulates IL-17 and aryl hydrocarbon receptor signalling pathways in human and mouse T cells through EP4/EP2-cAMP-PKA signalling, necessary for generation of pathogenic Th17 cells (Yao et al., 2009; Boniface et al., 2009; Lee et al., 2019; Robb et al., 2018) . Given that SARS-CoV-2 infection specifically upregulates IL-17F signalling and aryl hydrocarbon receptor signalling (Zhou et al., 2020e) , PGE2 is assumed to promote inflammatory Th17 cell expansion and function in COVID-19.

There are mixed findings regarding Treg cells in COVID-19. Reduction of Treg cell frequencies was observed in severe COVID-19 patients compared to non-severe patients (Qin et al., 2020; Chen et al., 2020a) , but Shi et al. reported an increase in Treg cell numbers in peripheral blood of mild COVID-19 patients compared to the control group and there was no difference in Treg cell numbers between mild/moderate and severe patients (Shi et al., 2020b) .

Both stimulatory and inhibitory effects of PGE2 on human Treg cell generation and suppressive function were observed (Schiavon et al., 2019; Li et al., 2019; Yao unpublished observations) .

The definitive functions of PGE2 on Treg cells in peripheral blood and lungs of COVID-19 patients remain to be determined.

Like T cells, NK cells are also depleted in peripheral blood of severe but not mild COVID-19 patients Wen et al., 2020; Wilk et al., 2020) . NK cell activation may also be impaired in COVID-19 patients due to down-regulation of CD107a and cytokines such as IFN- and TNF-α, but increased expression of NKG2A/CD94 that inhibits NK cell cytotoxicity . These studies suggest that NK cell numbers and function are impaired in severe COVID-19 patients. PGE2 was found to inhibit not only NK cell production of IFN-, but also myeloid cell production of IL-12 that is required for IFN- production through the EP4 receptor (Van Elssen et al., 2011) . The PGE2-EP4-cAMP signalling pathway also suppresses the cytolytic activity of NK and CD8 + T cells by increasing expression of NKG2A/CD94 (Park et al., 2018; Holt et al., 2011; Zeddou et al., 2005) .

Moreover, PGE2 inhibits CXCR3 ligands such as CXCL9 and CXCL10 from antigenpresenting cells, preventing NK cell migration (Gustafsson et al., 2011) . It is thus likely that PGE2 both directly and indirectly inhibits NK cell migration to the lung, activation and cytotoxic function in the context of COVID-19, however this remains to be verified.

Most human lung cells including stromal (fibroblasts), immune (monocytes, macrophages and lymphocytes) and vascular endothelial cells express PGI2 synthase (PGIS) and the PGI2 receptor IP (Figure 2) . As PGI2 also activates the cAMP-PKA signalling pathway like PGE2-EP2/EP4 signalling, it is assumed that these two molecules may share similar effects on modulation of immune and inflammatory responses (reviewed in Dorris and Peebles, 2012) although PGI2 is under-studied compared to PGE2. Firstly, PGI2 likely suppresses virus (e.g. RSV)-induced type I IFN production in the lung, which contributes to protection against viral infection (Hashimoto et al., 2004; Toki et al., 2013) . Overexpression of PGIS in bronchial epithelium decreased viral replication and limited weight loss whilst IP deficiency exacerbated RSV-induced weight loss with delayed viral clearance and had greater IFN- and  protein expression post RSV challenge (Hashimoto et al., 2004; Toki et al., 2013) . Secondly, like PGE2, PGI2-IP signalling also synergises with inflammatory cytokines (e.g. TNF- and IL-1)-activated NF-B for production of IL-6 in stromal cells (Honda et al., 2006) . Whereas, opposite to PGE2, PGI2 has also been indicated to down-regulate TNF- and CCL2 and thus to reduce recruitment of CCR2-expressing monocytes and macrophages to inflammation sites (Kumei et al., 2018) . Thirdly, PGI2 has also been reported to modulate adaptive T cell responses, e.g. promoting inflammatory IFN--producing Th1 and IL-17-producing Th17 cells (Nakajima et al., 2010; Zhou et al., 2012; Truchetet et al., 2012) . Lastly, PGI2 stimulates Ca 2+ efflux through IP-activated cAMP, counteracting platelet activation (e.g. induced by TXA2), which is also akin to effects of the PGE2-EP4 pathway. The capacity of PGI2 on regulation of immune and inflammatory responses thus have implications in COVID-19.

There are many therapeutic strategies to combat COVID-19 have been attempted via clinical trials. The main targets include (1) SARS-CoV-2 attachment and entry to human cells (e.g. the TMPRSS2 inhibitor Camostat mesylate, viral fusion inhibitors such as hydroxychloroquine) and viral replication (e.g. Remdesivir, Lopinavir etc); (2) systemic immune responses, for example, biologics (e.g. anti-IL-6, anti-TNF, anti-IL-1, anti-IFN- or small molecule inhibitors); and (3) hyperinflammation such as steroids (e.g. dexamethasone) and NSAIDs.

Trials using antibodies targeting cytokines or chemokines aim to block inflammatory immune cell migration and function and subsequently to reduce the cytokine storm-induced systemic inflammation. As a result, down-regulation of inducible COX-2 and mPGES-1 as well as PG biosynthesis is also expected as discussed in above sections. Asides the small pilot trial administering Celebrex to COVID-19 patients , another clinical trial has been registered as of 9 th July 2020 proposed to use naproxen in critically ill COVID-19 patients (https://clinicaltrials.gov/ct2/show/NCT04325633). As an inhibitor of both COX-2 and Influenza A virus nucleoprotein, naproxen has been shown to reduce mortality of patients with H3N2 influenza infection when administered in combination with clarithromycin and oseltamivir in a recent clinical trial (Hung et al., 2017) . It is thus expected that naproxen may reduce the mortality associated with critical COVID-19 patients via both COX-independent anti-viral transcription/replication and COX-2-dependent anti-inflammatory effects (https://clinicaltrials.gov/ct2/show/NCT04325633). Although corticosteroids are not recommended for treatment of SARS (Stockman et al., 2006) , there are many clinical trials proposed to use steroids in COVID-19 patients (https://clinicaltrials.gov). Strikingly, a very recent large-scale clinical trial showed that low dose dexamethasone (6 mg once daily) reduced deaths by one third in ventilated patients with COVID-19 and by one fifth in other COVID-19 patients who received oxygen only, whilst no benefit was observed in COVID-19 patients not requiring respiratory support (Horby et al., 2020) . Given that corticosteroids including dexamethasone inhibit PG (especially PGE2) production from various human tissues such as gut and lung (Aksoy, et al., 1999; Hawkey and Truelove, 1981; Ogushi et al., 1987) , results from this clinical trial are promising for COVID-19 therapeutic strategies targeting PG pathways. Corticosteroids suppress PG production through inhibition of enzymatic activities of PLA2 and COX-2, but not COX-1 (Zhang et al., 1999) . Dexamethasone represses COX-2 expression by both transcriptional and post-transcriptional mechanisms, i.e., dexamethasone reduces COX-2 gene expression through thyroid hormone receptor interfering the binding of NF-κB to the COX-2 gene promoter and decreases COX-2 mRNA stability via mechanisms involving preferential loss of polyadenylated mRNA, resulting in switching off mRNA translation and protein synthesis (Newton et al., 1998; Barnes, 2006) . Of note, despite inhibition of COX-2 by both NSAIDs and steroids, they have different in vivo actions in managing inflammatory diseases. For example, while dexamethasone only had moderate effects on reducing mortality of severe/critical (but not non-severe) COVID-19 patients (Horby et al., 2020) , celebrex reduced disease severity and improved remission in both non-severe and severe COVID-19 patients , indicating different clinical outcomes from use of NSAIDs and other anti-inflammatory agents. Yet, further studies are highly warranted to clarify the clinical safety and efficiency of these two families of anti-inflammatory drugs and to understand the underlying immunomodulatory mechanisms.

Here Importantly, PGs are more likely to modulate host immune and inflammatory responses activated by virus pathogens. PGs, especially PGE2, can foster or restrain both innate and adaptive immune reactions. For example, PGE2 can repress type I IFN signalling, cytotoxic T cell responses, NET formation, inflammasome activation and inflammatory cytokine production, whereas it can also contribute to inflammatory Th17 responses, NF-B activation and related inflammatory cytokine production. These effects of PGs largely rely on the context and microenvironments such as strength (e.g. viral load) and timing of stimuli, organ locations, and responding cell types. Given the critical role of cytokine storms in COVID-19 immunopathology and the context-dependent regulation of cytokine production by PGs, it is imperative to understand the chief cellular sources of cytokines in the lung and peripheral blood, key stimuli (e.g. SARS-CoV proteins or peptides), and decipher the cytokine secretion kinetics. Results from such studies may be insightful for considerations on when exactly NSAIDs could be administered to COVID-19 patients to tackle hyperinflammation whilst minimising their adverse side effects. Furthermore, as NSAIDs unselectively block all PG pathways by targeting COXs (that may be related to unfavourable side effects), targeting respective PG synthesis or PG receptors may help to avoid NSAIDs' adverse side effects. By Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., et al. (2004) . Neutrophil Extracellular Traps Kill Bacteria. Science 303: 1532-1535.

Capuano, A., Scaglione, F., Berrino, L., Del Re, M., Bernardini, R., Chiamulera, C., et al. (2020) . Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections. Pharm Adv 02: https://doi.org/10.36118/pharmadvances.01.2020.03

Castro, V.M., Ross, R.A., McBride, S.M., and Perlis, R.H. (2020) . Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv 2020 MedRxiv .04.11.20061994. https://doi.org/10.1101 MedRxiv /2020 Channappanavar, R., Zhao, J., and Perlman, S. (2014) . T cell-mediated immune response to respiratory coronaviruses. Immunol Res 59: 118-128.

Cui, S., Chen, S., Li, X., Liu, S., and Wang, F. (2020) . Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. https://doi.org/10.1111/jth.14830 Das, U.N. (2018) . Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: A review. Journal of Advanced Research 11: 57-66. Das, U.N. (2020) . Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? Arch. Med. Res. 51: 282-286.

Davis, J.S., Lee, H.Y., Kim, J., Advani, S.M., Peng, H.-L., Banfield, E., et al. (2017) . Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart 4: e000550.

Day, M. (2020) . Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ m1086.

Dehle, F.C., Mukaro, V.R., Jurisevic, C., Moffat, D., Ahern, J., Hodge, G., et al. (2013) . Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2? PLoS ONE 8: e61573. Delaney, V.B., and Segel, D.P. (1985) . Indomethacin-induced renal insufficiency: recurrence on rechallenge. South. Med. J. 78: 1390-1392.

Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., et al. (2020) . 

Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells

Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

Indomethacin has a potent antiviral activity against SARS coronavirus

Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR

Prostaglandin E2-EP2-NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms

Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

How corticosteroids control inflammation: Quintiles Prize Lecture

COVID-19 update: Covid-19-associated coagulopathy

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Antiinflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Prostaglandin E₂ possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts

Peptidoglycan-induced IL-6 production in RAW 264.7 macrophages is mediated by cyclooxygenase-2, PGE2/PGE4 receptors, protein kinase A, I kappa B kinase, and NF-kappa B

Clinical and immunological features of severe and moderate coronavirus disease 2019

Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation. Preprints

Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Cell entry of bovine ephemeral fever virus requires activation of Src-JNK-AP1 and PI3K-Akt-NF-κB pathways as well as Cox-2-mediated PGE2 /EP receptor signalling to enhance clathrin-mediated virus endocytosis

Prostaglandin E2 Induces IL-6 and IL-8 Production by the EP Receptors/Akt/NF-κB Pathways in Nasal Polyp-Derived Fibroblasts

Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages

Origin and evolution of pathogenic coronaviruses

Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin

Differences in PGE2 production between primary human monocytes and differentiated macrophages: role of IL-1β and TRIF/IRF3

Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement

Facilitation of IL-22 production from innate lymphoid cells by prostaglandin E2 prevents experimental lung neutrophilic inflammation

Misguided drug advice for COVID-19

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. The Lancet Respiratory Medicine

Risk factors for hospital admission related to COVID-19 in inflammatory rheumatic diseases

Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease

Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease

Novel cell death program leads to neutrophil extracellular traps

Increases in inflammatory and CD14dim/CD16pos/CD45pos patrolling monocytes in sepsis: correlation with final outcome

Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor

Prediction of Novel Inhibitors of the Main Protease (Mpro) of SARS-CoV-2 through Consensus Docking and Drug Reposition

Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Prostaglandin E(2) (PGE2) suppresses natural killer cell function primarily through the PGE(2) receptor EP4

Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collageninduced arthritis

Celebrex adjuvant therapy on COVID-19: An experimental study

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea

Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts

IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Lessons from SARS: control of acute lung failure by the SARS receptor ACE2

Prostaglandin I2 suppresses the development of diet-induced nonalcoholic steatohepatitis in mice

Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe Asthma

SARS-CoV-2 productively infects human gut enterocytes

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Nonsteroidal Anti-Inflammatory Drug without Antibiotics for Acute Viral Infection Increases the Empyema Risk in Children: A Matched Case-Control Study

Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome

T cell-intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cell-driven inflammation

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Coagulation abnormalities and thrombosis in patients with COVID-19

Prostaglandin E2 signal inhibits T regulatory cell differentiation during allergic rhinitis inflammation through EP4 receptor

Activation of the EP₄ prostanoid receptor induces prostaglandin E₂ and pro-inflammatory cytokine production in human airway epithelial cells

Induction of proinflammatory genes by serum amyloid A1 in human amnion fibroblasts

Age-Associated Increase in Skin Fibroblast-Derived Prostaglandin E2 Contributes to Reduced Collagen Levels in Elderly Human Skin

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Non-steroidal anti-inflammatory drugs and covid-19

Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial

Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Reference Module in Life Sciences

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

) exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation

Calcium-dependent stimulation of platelet aggregation by PGE 2

Serum amyloid A (SAA) protein enhances formation of cyclooxygenase metabolites of activated human monocytes

Elevated prostaglandin E2 post-bone marrow transplant mediates interleukin-1β-related lung injury

Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition

COVID-19: consider cytokine storm syndromes and immunosuppression

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations

The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?

Inhibition of Cytosolic Phospholipase A2α Impairs an Early Step of Coronavirus Replication in Cell Culture

Prostaglandin I2-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity

Multifaceted roles of PGE2 in inflammation and cancer

Slco2a1 deficiency exacerbates experimental colitis via inflammasome activation in macrophages: a possible mechanism of chronic enteropathy associated with SLCO2A1 gene

Genetic and pharmacological analysis of prostanoid receptor function

NF-κB-dependent IL-8 induction by prostaglandin E(2) receptors EP(1) and EP(4)

Repression of Cyclooxygenase-2 and Prostaglandin E2Release by Dexamethasone Occurs by Transcriptional and Post-transcriptional Mechanisms Involving Loss of Polyadenylated mRNA

Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome

PGE2 and PGF2 alpha content in bronchoalveolar lavage fluid obtained from patients with eosinophilic pneumonia

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK)

Cyclooxygenase inhibitors: From pharmacology to clinical read-outs

Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23

Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production

Innate Immune Response of Human Alveolar Type II Cells Infected with Severe Acute Respiratory Syndrome-Coronavirus

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats

Dysregulation of immune response in patients with COVID-19 in Wuhan

Adipose-derived mesenchymal stem cells modulate CD14++CD16+ expression on monocytes from sepsis patients in vitro via prostaglandin E2

Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy

Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years

Prostaglandins and Inflammation

Invertebrate extracellular phagocyte traps show that chromatin is an ancient defence weapon

Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis

Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection

Prostaglandin E2 As a Modulator of Viral Infections

Microenvironment tailors nTreg structure and function

Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Augments Inflammasome Activation and M1 Polarization in Macrophages Infected With Salmonella Typhimurium and Yersinia enterocolitica

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Neutrophil calprotectin identifies severe pulmonary disease in COVID-19

Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

The classical CD14 ++ CD16 − monocytes, but not the patrolling CD14 + CD16 + monocytes, promote Th17 responses to Candida albicans

Hypothesis: mPGES-1-Derived Prostaglandin E2, a So Far Missing Link in COVID-19 Pathophysiology? Preprints

Prostaglandin D2 inhibits the aggregation of human platelets

Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages

SARS: systematic review of treatment effects

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

The trinity of COVID-19: immunity, inflammation and intervention

The SARS-CoV-2 spike protein primes inflammasome-mediated interleukin-1-beta secretion in COVID-19 patient-derived macrophages (Preprint)

NETs By-products and Extracellular DNA May Play a Key Role in COVID-19 Pathogenesis: Incidence on Patient Monitoring and Therapy

Does the newly observed inflammatory syndrome in children demonstrate a link between uncontrolled neutrophil extracellular traps formation and COVID-19?

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Signaling Inhibits Lung Type I Interferon Expression by RSV Infection

Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19

Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis

Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation

The lung as a privileged site for the beneficial actions of PGE2

Virus-induced inflammasome activation is suppressed by prostaglandin D2/DP1 signaling

Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection

Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein (Biochemistry

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Role of prostanoids in gastrointestinal cancer

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-λ production

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Covid-19 and thrombosis: what do we know about the risks and treatment

Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques

World Health Organisation, Coronavirus disease (COVID-19) situation report

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention

Macrophages in Tissue Repair, Regeneration, and Fibrosis

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo

Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1β-driven venous thrombosis

Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2)

Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication

Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers

Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein

Prostaglandin E₂ promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase

Prostaglandin-cytokine crosstalk in chronic inflammation

Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion

Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop

The Induction of Pro-IL-1β by Lipopolysaccharide Requires Endogenous Prostaglandin E2 Production

Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome (Infectious Diseases (except HIV/AIDS)). meRixv

Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids

Viral and host factors related to the clinical outcome of COVID-19

Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice

Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice

Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2 (Bioinformatics)

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Prostaglandin I2 Signaling Drives Th17 Differentiation and Exacerbates Experimental Autoimmune Encephalomyelitis

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Coronavirusesdrug discovery and therapeutic options

Neutrophil extracellular traps and thrombosis in COVID-19

This article is protected by copyright. All rights reserved.

The authors declare no conflicts of interest. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.Gladding, P.A., Webster, M.W.I., Farrell, H.B., Zeng, I.S.L., Park, R., and Ruijne, N. (2008) . The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol. 101: 1060-1063.Gomeni, R., Xu, T., Gao, X., and Bressolle-Gomeni, F. (2020) . Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/s10928-020-09690-4 Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., et al. (2020) . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9Gouveia- Figueira Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Pere, H., et al. (2020) . Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients (Infectious Diseases (except HIV/AIDS)). medRixv. https://doi.org/10.1101 /2020.04.19.20068015 Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J., and Goor, H. van (2004) . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology 203: 631-637.Hashimoto, K., Graham, B.S., Geraci, M.W., FitzGerald, G.A., Egan, K., Zhou, W., et al. (2004) . Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J. Virol. 78: 10303-10309.Hawkey, C.J., and Truelove, S.C. (1981) . Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay. Hertz, A.L., Bender, A.T., Smith, K.C., Gilchrist, M., Amieux, P.S., Aderem, A., et al. (2009) . Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocytederived macrophages. Proc. Natl. Acad. Sci. U.S.A. 106: 21978-21983.